Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.
Study Type
OBSERVATIONAL
Enrollment
1,897
Observational
To measure the rates of non-Hodgkin's lymphoma (NHL) and infections that require hospitalization occurring in psoriasis patients treated with alefacept
Time frame: At six month intervals for five years
To estimate the rates of lung cancer, breast cancer (female), prostate cancer, colorectal cancer, melanoma and active tuberculosis within a population of patients with psoriasis treated with alefacept.
Time frame: At six month intervals for five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Total Skin and Beauty Dermatology Center
Birmingham, Alabama, United States
Janet Cash
Birmingham, Alabama, United States
Bay Shore Dermatology & Laser Surgery Center
Fairhope, Alabama, United States
Eric Baum
Gadsden, Alabama, United States
Ruth A Yates
Huntsville, Alabama, United States
Mobile Dermatology
Mobile, Alabama, United States
English Dermatology Centers
Phoenix, Arizona, United States
Scottsdale Dermatology
Scottsdale, Arizona, United States
Sheftel & Associates Dermatology
Tucson, Arizona, United States
Ozark Dermatology Clinic
Fayetteville, Arkansas, United States
...and 258 more locations